News Archive

9.13.21 - Real-world data point to utility of assay for reducing unnecessary prostate biopsies

7.7.20 - Cleveland Diagnostics announces the initial commercial release of its blood-based IsoPSA® test to assess a patient’s risk of having high-grade cancer. IsoPSA is now available to clinicians in the Cleveland Clinic system. Samples will be processed in Cleveland Diagnostics’ newly certified CLIA lab.

2.20.20 - Cleveland Diagnostics publishes online in Urology Practice a manuscript entitled “Decision Analysis Model Comparing Cost of IsoPSA™ vs Repeat Biopsy for Detection of Clinically Significant Prostate Cancer in Men with Previous Negative Findings on Biopsy,” suggesting a significant reduction in unnecessary repeat biopsies and the generation of significant cost savings to the health care system.

10.21.19 - Cleveland Diagnostics’ Revamped PSA Test Deemed FDA Breakthrough Device

6.1.19 - Clinical Validation of IsoPSA™, a Single Parameter, Structure Based Assay for Improved Detection of High Grade Prostate Cancer

4.19 - Preliminary Evaluation of PI-RADS Score Versus IsoPSA for Detection of High Grade Prostate Cancer

4.19 - IsoPSA is a Sensitive Assay for Cribriform and Intraductal Carcinoma

3.11.19 - Clinical Validation of IsoPSA, a Single Parameter, Structure Based Assay for Improved Detection of High Grade Prostate Cancer

11.6.18 - PSA isoform assay predicts high-grade PCa

10.29.18 - Prostate Cancer Today: A 2-Minute Update for Physicians

9.20.18 - IsoPSA: One Step Closer to a Better Prostate Cancer Blood Test

8.1.18 - The Changing Landscape of Prostate Cancer Screening

6.11.18 - Men’s Health Week 2018: Blood test detecting high-grade prostate cancers may bypass nearly half of all biopsies

6.7.18 - IsoPSA Blood Test Shows Promising Results for Early Prostate Cancer Diagnosis

5.24.18 - Blood test superior to PSA for detecting high-grade prostate cancer

5.23.18 - Newer PSA Test Reportedly Would Prevent 40 Percent of Biopsies

5.18.18 - Novel Blood Test Improves Detection of High-Grade Prostate Cancer

11.28.17 - Genomic Health and Cleveland Diagnostics Announce Strategic Collaboration to Develop and Commercialize New Prostate Cancer Tests

7.1.17 - IsoPSA Outperforms PSA in Distinguishing Cancer From Benign Conditions, High- Versus Low-Grade Cancer

6.16.17 - The Latest Cancer Research News to Cheer About

6.1.17 - Improved Method of Using Serum PSA to Diagnose Prostate Cancer is Promising

5.30.17 - Blood-based assay superior to PSA for prostate cancer diagnosis

5.25.17 -  IsoPSA Test Superior to PSA in Prostate Cancer Detection

5.17.17 - This New, Easy Prostate Cancer Test Can Reduce Unnecessary Biopsies By 50 Percent

5.16.17 - New prostate cancer test could reduce unnecessary, painful biopsies by 50% - saving sufferers from urinary incontinence and erectile dysfunction

5.15.17 - IsoPSA could be better predictor of prostate cancer

5.15.17 - Study: New blood test is more accurate in predicting prostate cancer risk than PSA

5.11.17 - New PSA test examines protein structures to detect prostate cancers

4.25.17 - Structure-based IsoPSA Assay Outperforms PSA Concentration for Prostate Cancer Diagnosis

4.24.17 - Structure-based IsoPSA assay outperforms PSA concentration for prostate cancer diagnosis

3.25.17 - The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based Assay of Total Prostate-specific Antigen: A Preliminary Report

2.7.17 -  Dr. Arnon Chait, CEO of Cleveland Diagnostics, interviewed by ILTV Israel Daily

10.10.16 - IsoPSA, a New Biomarker Test, Differentiates High- and Low-Grade Prostate Cancer, Improves Diagnostic Accuracy

7.7.16 - New prostate cancer test strives to slash biopsies

5.27.16 -  Cleveland Diagnostics Study Finds Its IsoPSA Test Outperforms Standard PSA Testing

5.13.16 - AUA 2016: IsoPSA, a Novel, Structure-Based Biomarker Test for Prostate Cancer, Explored in a Multicenter Prospective Trial

5.10.16 - New PSA Test Examines Protein Structures To Detect Prostate Cancers

5.10.16 - AUA 2016 - IsoPSA: Initial Clinical Performance Evaluation of a Novel Structure-Based Biomarker For Prostate Cancer in a Multicenter Prospective Trial for Gleason = 7

4.30.15 -  Cleveland Clinic Innovations creates thriving companies out of research

3.20.15 - Cleveland Clinic spinout raises $2M for cancer-screening blood tests

11.6.13 -  Cleveland Clinic Innovations forms new company to create cancer screening tests

11.6.13 -  Cleveland Clinic's next commercial venture: blood tests for prostate, ovarian, breast cancers

8.26.11 - New prostate cancer screening test shows promise for diagnosis